RELATING TO FOOD AND DRUGS -- UNIFORM CONTROLLED SUBSTANCES ACT
Impact
The enactment of H7756 is contingent upon the rescheduling of psilocybin by the U.S. Food and Drug Administration (FDA). If approved, the Rhode Island Department of Health will be required to establish regulations governing cultivation, distribution, and medical prescription of psilocybin. This could significantly alter the legal landscape around mental health treatments in the state, potentially providing new avenues for patients while also imposing certain regulations on its cultivation and use.
Summary
House Bill H7756, introduced in 2026, aims to amend the current law on controlled substances in Rhode Island by allowing the secure cultivation of psilocybin within a person's residence for personal use. The bill specifically excludes up to one ounce of psilocybin from the provisions of the Uniform Controlled Substances Act, provided it is cultivated or shared between individuals under specified conditions. This change reflects a growing trend toward improving access to psilocybin, particularly for individuals dealing with serious mental or behavioral health disorders.
Contention
Notable points of contention surrounding H7756 involve discussions about the implications of legalizing psilocybin use and its impact on public health and safety. Supporters argue that this bill could improve mental health treatment options, especially for those without access to effective medications. Critics, however, may raise concerns regarding the risks of misuse and the standards for cultivation and distribution, emphasizing the need for robust regulatory frameworks to prevent abuse.
Amends current law on controlled substances to permit psilocybin to be cultivated within a person's residence for personal use and contingent on the US FDA's program, mandate that RI department of health establish rules regulations.
Revises sections of the uniform controlled substances act to remove specific opioid dosage requirements, revises the uniform controlled substances act in accordance with current standards of professional practice and would repeal chapter 37.4 of title 5.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.
Amends the types of products which pharmacists may prescribe as substitute drugs or products to include "devices and supplies" and "therapeutically equivalent drugs and pharmaceuticals".
Amends the types of products which pharmacists may prescribe as substitute drugs or products to include "devices and supplies" and "therapeutically equivalent drugs and pharmaceuticals."
Directs the state board of pharmacy to annually identify up to fifteen prescription drugs with increased costs and provide the list to the attorney general to obtain reasons for the cost increases.
A bill for an act relating to the production of psilocybin and the administration of psilocybin to persons with post-traumatic stress disorder, and providing penalties.(See HF 978.)
(New Title) establishing a medical psilocybin advisory board to assess the advantages and disadvantages of the use of psilocybin for therapeutic purposes.